Crossmark

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Crossref DOI link: https://doi.org/10.1186/s12885-017-3720-8

Published Online: 2018-01-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Jianya

Zheng, Jing

Zhang, Xiaochen

Zhao, Jing

Zhu, Yanping

Shen, Qian

Wang, Yuehong

Sun, Ke

Zhang, Zeying

Pan, Zhijie

Shen, Yihong

Zhou, Jianying
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81472171)

National Natural Science Foundation of China (81672299)

State Scholarship Fund of China (201308330145)

Project of Health and Family Planning Commission of Zhejiang Province, China (2017KY058)